Transforming healthcare delivery across patients, payers, and healthcare systems
The patient experiences the most direct "quality of life" improvements.
Approximately 10% of the population suffers from needle phobia, which can lead to treatment avoidance. Oral delivery removes this critical barrier to therapy, enabling patients who might otherwise refuse treatment to access life-changing biologics.
Patients can take their medication at home, at work, or while traveling, rather than scheduling appointments at infusion centers or clinics. This eliminates the disruption to daily life, reduces time away from work and family, and puts patients in control of their treatment schedule.
Oral delivery avoids the bruising, swelling, and localized pain common with subcutaneous injections and IV lines. Patients no longer experience injection-site reactions, discomfort from needle insertion, or the anxiety associated with repeated skin punctures.
Bypasses the risk of cannula-related infections or secondary bacterial/fungal infections associated with repeated skin punctures. This is particularly important for immunocompromised patients or those on long-term therapy who face cumulative infection risks.
Research suggests patients are more likely to stick to a long-term treatment plan when it involves a simple pill rather than a complex or painful injection schedule. Better adherence leads to improved therapeutic outcomes, fewer disease flares, and reduced healthcare utilization.
For certain drugs like insulin, oral delivery can better mimic the body's natural pathways (portal circulation to the liver) rather than systemic absorption via fat tissue. This first-pass hepatic exposure more closely resembles endogenous hormone patterns, potentially offering superior efficacy and fewer side effects.
Payers see significant value in reducing the "hidden" costs of healthcare.
Oral formulations often do not require the same sterile manufacturing environments as parenterals, potentially lowering the base price of the drug. Simplified manufacturing processes, reduced cold-chain requirements, and elimination of specialized packaging can all contribute to lower acquisition costs.
Payers no longer have to reimburse for nursing time, facility fees for infusion centers, or specialized equipment (needles, syringes, IV kits). These "hidden costs" can add $500-$2,000 per infusion visit, representing substantial savings when multiplied across thousands of patients and regular dosing schedules.
Lowering the rate of injection-site infections or infusion-related adverse reactions reduces the cost of secondary care. Treatment of complications, emergency department visits, and hospitalizations for severe reactions all contribute to the total cost of care that oral delivery can help avoid.
The introduction of oral versions of existing biologics can drive competition and lower prices across the therapeutic class. As oral alternatives enter the market, they create pricing pressure on injectable formulations and encourage innovation in drug delivery across the industry.
The broader system benefits from improved efficiency and resource allocation.
Frees up nurses and clinicians from the time-consuming task of administering injections and monitoring patients during long infusions. Staff can redirect their expertise toward patients with more acute needs, improving overall care delivery and reducing provider burnout from repetitive tasks.
Reduces the need for dedicated infusion chairs and clinic space, allowing hospitals to focus resources on patients with more acute needs. Infusion centers represent significant capital investment and operational overhead; oral biologics free this infrastructure for surgeries, procedures, and critical care.
Eliminates the medical waste associated with disposables like needles, biohazard sharps containers, and plastic IV tubing. This reduces environmental impact, lowers disposal costs, and decreases the risk of needlestick injuries among healthcare workers handling biohazardous waste.
Because oral medications are easier to prescribe and take, doctors may be able to start effective biologic therapy earlier in the disease progression, potentially preventing long-term disability or expensive hospitalizations. Earlier intervention often leads to better outcomes, reduced disease progression, and lower lifetime healthcare costs.
Ready to learn more about our oral biologic platform?
Contact Us